The effects of cefazolin on cirrhotic patients with acute variceal hemorrhage after endoscopic interventions

被引:18
作者
Xu, Huang-Wei [1 ]
Wang, Jing-Houng [1 ]
Tsai, Moan-Shane [2 ]
Wu, Keng-Liang [1 ]
Chiou, Shue-Shian [1 ]
Changchien, Chi-Sin [1 ]
Hu, Tsung Hui [1 ]
Lu, Sheng-Nan [1 ]
Chuah, Seng-Kee [1 ]
机构
[1] Chang Gung Univ Coll Med, Chang Gung Mem Hosp Kaohsiung Med Ctr, Div Hepatogastroenterol, Dept Internal Med, Kaohsiung 833, Taiwan
[2] Chang Gung Univ Coll Med, Chang Gung Mem Hosp Kaohsiung Med Ctr, Div Infect Dis, Dept Internal Med, Kaohsiung 833, Taiwan
来源
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES | 2011年 / 25卷 / 09期
关键词
Cefazolin; Cirrhosis; Variceal hemorrhage; Bacterial infections; Rebleeding; PREVENTS BACTERIAL-INFECTION; ANTIBIOTIC-PROPHYLAXIS; ESOPHAGEAL-VARICES; NORFLOXACIN; SCLEROTHERAPY; RISK;
D O I
10.1007/s00464-011-1642-0
中图分类号
R61 [外科手术学];
学科分类号
摘要
The American Association for the Study of Liver Diseases (AASLD) guidelines recommend that antibiotic prophylaxis should be instituted in any patient with cirrhosis and gastrointestinal hemorrhage, and that oral norfloxacin, intravenous ciprofloxacin, and ceftriaxone are preferable. However, the antimicrobial spectrum of the first generation of cephalosporins (cefazolin) covers a wide range of bacteria species, including community-acquired strains of Escherichia coli and Klebsiella pneumoniae, but their efficacy as prophylactic antibiotics in cirrhotic patients with acute hemorrhage was seldom warranted in the literature. This study aimed to explore the effects of cefazolin on the outcome of cirrhotic patients with acute variceal hemorrhage after endoscopic interventions. A cross-sectional, retrospective chart review study was conducted on cirrhotic patients with acute variceal hemorrhage who underwent endoscopic procedures in a medical center. Cirrhotic patients who did not receive antibiotics were classified as group A (n = 63) while patients who received intravenous cefazolin 1 g q8 h for 2-7 days were classified as group B (n = 50). The end points were the prevention of infection, length of hospital stay, time of rebleeding, and death. A total of 113 patients were studied (male/female: 82/31; age: 56.8 +/- A 13.5 years). The incidence of infection (including proven infections) and bacteremia were significantly lower in group B patients (38.1% vs. 16.0%, P = 0.010; 17.5% vs. 4.0%, P = 0.026; 9.5% vs. 0%, P = 0.033, respectively). The no prophylactic antibiotics treatment was the independent risk factor. There was no significant difference between the two groups with respect to the source of bleeding, type of endoscopic intervention, length of hospital stay, and mortality. Actuarial probability of remaining free of early rebleeding (< 7 days) was P = 0.105 by log-rank test for all cirrhosis patients and P = 0.085 for Child-Pugh class A patients. The use of cefazolin in cirrhotic patients after endoscopic interventions for acute variceal hemorrhage reduced infections. A trend of actuarial probability of remaining free of early rebleeding (< 7 days) was observed, especially in Child-Pugh class A patients. This study may be hampered by the small sample size and more large-scale studies are mandatory.
引用
收藏
页码:2911 / 2918
页数:8
相关论文
共 26 条
[1]   BACTERICIDAL ACTIVITY AND PHARMACOLOGY OF CEFAZOLIN [J].
BERGERON, MG ;
BRUSCH, JL ;
BARZA, M ;
WEINSTEIN, L .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1973, 4 (04) :396-401
[2]   Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding:: A meta-analysis [J].
Bernard, B ;
Grangé, JD ;
Khac, EN ;
Amiot, X ;
Opolon, P ;
Poynard, T .
HEPATOLOGY, 1999, 29 (06) :1655-1661
[3]   SYSTEMIC ANTIBIOTIC-THERAPY PREVENTS BACTERIAL-INFECTION IN CIRRHOTIC-PATIENTS WITH GASTROINTESTINAL HEMORRHAGE [J].
BLAISE, M ;
PATERON, D ;
TRINCHET, JC ;
LEVACHER, S ;
BEAUGRAND, M ;
POURRIAT, JL .
HEPATOLOGY, 1994, 20 (01) :34-38
[4]   Bacterial infection in patients with advanced cirrhosis:: a multicentre prospective study [J].
Borzio, M ;
Salerno, F ;
Piantoni, L ;
Cazzaniga, M ;
Angeli, P ;
Bissoli, F ;
Boccia, S ;
Colloredo-Mels, G ;
Corigliano, P ;
Fornaciari, G ;
Marenco, G ;
Pistarà, R ;
Salvagnini, M ;
Sangiovanni, A .
DIGESTIVE AND LIVER DISEASE, 2001, 33 (01) :41-48
[5]   Effect of fluoroquinolone on the enhanced nitric oxide-induced peripheral vasodilation seen in cirrhosis [J].
ChinDusting, JPF ;
Rasaratnam, B ;
Jennings, GLR ;
Dudley, FJ .
ANNALS OF INTERNAL MEDICINE, 1997, 127 (11) :985-988
[6]   Bacterial translocation of enteric organisms in patients with cirrhosis [J].
Cirera, I ;
Bauer, TM ;
Navasa, M ;
Vila, J ;
Grande, L ;
Taurá, P ;
Fuster, J ;
García-Valdecasas, JC ;
Lacy, A ;
Suárez, MJ ;
Rimola, A ;
Rodés, J .
JOURNAL OF HEPATOLOGY, 2001, 34 (01) :32-37
[7]  
DAMICO G, 1986, FRONTIERS GASTROINTE, P247
[8]   Bacterial infections in cirrhosis:: Epidemiological changes with invasive procedures and norfloxacin prophylaxis [J].
Fernández, J ;
Navasa, M ;
Gómez, J ;
Colmenero, J ;
Vila, J ;
Arroyo, V ;
Rodés, J .
HEPATOLOGY, 2002, 35 (01) :140-148
[9]   Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage [J].
Fernandez, Javier ;
Del Arbol, Luis Ruiz ;
Gomez, Cristina ;
Durandez, Rosa ;
Serradilla, Regina ;
Guarner, Carlos ;
Planas, Ramon ;
Arroyo, Vicente ;
Navasa, Miguel .
GASTROENTEROLOGY, 2006, 131 (04) :1049-1056
[10]   Prevention and management of Gastroesophageal varices and variceal Hemorrhage in cirrhosis [J].
Garcia-Tsao, Guadalupe ;
Sanyal, Arun J. ;
Grace, Norman D. ;
Carey, William .
HEPATOLOGY, 2007, 46 (03) :922-938